Investigating the Mu:Kappa Opioid Receptor Imbalance in Alcohol Use Disorder
NCT05957159
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
The primary objective of this multimodal positron emission tomography (PET) study is to use PET brain imaging to measure both MOR (Mu-Opioid receptors) and KOR (kappa-opioid receptors) in participants with alcohol use disorder (AUD) and to quantify the relationships between MOR and KOR, separately and jointly, to key clinical outcomes (e.g., craving, mood, withdrawal, time to lapse) during a quit attempt.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Alcohol Use Disorder
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Early Phase 1
- Ages
- 21 to 70 years
- Sex
- All
- Healthy volunteers
- Accepted
- Sponsor
- Yale University
- Last updated on ClinicalTrials.gov
- September 9, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Connecticut · 1
- Yale University · New Haven, CT
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.